Studies leading to the identification of ZD1839 (Iressa) : An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2001-07, Vol.11 (14), p.1911-1914
Hauptverfasser: BARKER, Andrew J, GIBSON, Keith H, HENTHORN, Lianne, RICHARDS, Laura, GRUNDY, Walter, GODFREY, Andrew A, BARLOW, Jeffrey J, HEALY, Mark P, WOODBURN, James R, ASHTON, Susan E, CURRY, Brenda J, SCARLETT, Lynn
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.
ISSN:0960-894X
1464-3405
DOI:10.1016/s0960-894x(01)00344-4